AzTrials
AzTrials

Endometriosis of UmbilicusUMBENDNCT05367258

Umbilical Endometriosis: a Comparison of Medical and Surgical Therapy and Pathogenetic Considerations

An observational study of Endometriosis of Umbilicus and Endometriosis in Scar of Skin, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Endometriosis is the presence of endometrial glands and stroma outside the uterine cavity. About 5% of women of reproductive age suffer from the disease. The pelvis is the most frequent site of endometriotic lesion and the most common pelvic localisations are peritoneal, ovarian, and deep infiltrating endometriosis. Read more about this study

Who is it for?
Ages 18 to 50 years, women only
What is being tested?
Patients satisfaction after medical and surgical treatment for umbilical endometriosis
How many people
50 participants
Where
1 siteItaly
Study dates
1 Mar 2022to 1 Jun 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: All the patients referred to our endometriosis clinic and/or underwent surgery from 1 January 1990 to 01 March 2022 with a diagnosis of umbilical endometriosis were selected.

Who may be able to join

  • women aged 18-50 years with a diagnosis of umbilical endometriosis, in the presence or absence of other endometriotic localizations, referred to our tertiary-care endometriosis center " Fondazione IRCCS Ospedale Maggiore Policlinico", Milan, from 1 January 1990 to 01 March 2022.

Who cannot join

  • Exclusion criteria are the presence of concomitant psychiatric disease, chronic intestinal disease (Chron's disease or ulcerative rectocolitis), or disease that may cause pelvic pain (e.g., pelvic venous varices and salpingitis outcomes).

Trial locations and contacts

1 site in 1 country.

Nicola Berlanda, Professor contact

0255032318

nicola.berlanda@policlinico.mi.it

Italy1 site, 1 recruiting
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    Milan, 20122

    Nicola Berlanda, Prof, 0255032318, nicola.berlanda@policlinico.mi.it

    Recruiting

Other trials in Italy

About this study

Endometriosis is the presence of endometrial glands and stroma outside the uterine cavity. About 5% of women of reproductive age suffer from the disease.

The pelvis is the most frequent site of endometriotic lesion and the most common pelvic localisations are peritoneal, ovarian, and deep infiltrating endometriosis. However, endometriosis can also localize outside the pelvis, for example involving the umbilicus, omentum, appendix, liver, diaphragm, pleura and lungs, vulva, and surgical scars.

Read more

The majority of extrapelvic endometriosis implants are located in the skin, and most of them are of iatrogenic origin, following laparotomy, laparoscopic procedures, and episiotomies; only a minority of cases are of primary origin.

Umbilical endometriosis is a very rare presentation of endometriosis (0.5-1% of cases of extrapelvic endometriosis).

Pathogenetic hypotheses of primary umbilical endometriosis include: hematic or lymphatic dissemination of endometrial cells from the peritoneum to the umbilicus through obliterated umbilical arteries; migration of endometrial cells through the venous or lymphatic circulation; metaplasia of urachus remnant or release of endometrial cells that during labor and delivery may contaminate the umbilical cord emergence. Secondary umbilical endometriosis is probably due to the proliferation and subsequent dissemination of iatrogenically implanted endometrial cells in laparotomy or laparoscopic scars. In 20% of cases, umbilical endometriosis is associated with pelvic endometriosis. In these patients, it is probable that endometriotic cells may migrate from the endometriotic implants to the umbilical site.

This migration process could be favored by fascia defects at the umbilical level. In fact, reports in the literature describe cases of umbilical endometriosis coexisting with umbilical hernia.

The clinical presentation consists of an umbilical nodule of variable color (red, blue, black, flesh-colored), ranging in size from 0.5 to 3 cm.

Pathognomonic symptoms are: bleeding and/or pain in the umbilical site of catamenial type, cutaneous hyperesthesia. Catamenial symptomatology associated with the nodule, which makes the diagnosis easier, is present in only 75% of cases.

In asymptomatic cases the differential diagnosis of the nodule of umbilical endometriosis is more difficult (hernia, hematoma, cyst, dermatological disorders, tumor metastasis).

Instrumental examinations useful for differential diagnosis and definition of nodule size include soft tissue ultrasound, CT scan and MRI.

Definitive diagnosis is only by histologic examination of the tissue. Exploratory laparoscopy is not indicated unless concomitant pelvic endometriosis is suspected.

The recommended treatment of umbilical endometriosis is surgical, consisting of complete removal of the endometriosis nodule, omphalectomy, and subsequent reconstruction of the umbilicus.

Recurrence rates after surgery are around 6% at 12 months in a large Japanese court, with no difference between taking and not taking postoperative hormonal therapy, while they are reduced to almost 0% in case of resection including a large portion of peritoneum.

Medical therapy, on the other hand, alleviates the associated algic symptoms by reducing the size of the nodule.

There are very few data on the efficacy of medical therapy; in a study with a very small number of cases an efficacy of 91.7% with dienogest and 51.1% with estroprogestinic pill is reported. There are no studies comparing medical and surgical therapy for the treatment of umbilical endometriosis.

Radical excision is recommended to avoid local recurrences and to avoid the risk of malignant transformation, although it is extremely rare (only 2 cases reported).

In literature, spontaneous resolution has been described in only one pregnant woman.

To date, few studies have evaluated umbilical endometriosis. Moreover, no study has ever formally compared the long-term efficacy of surgical or medical therapy for umbilical endometriosis.

This is a observational, retrospective/prospective and monocentric study; it is based on the review of medical records and on outpatient follow-up visits of patients in our clinic with umbilical endometriosis from 1990.

The principal aim of the study is to evaluate the effectiveness of medical and surgical treatments in terms of satisfaction, psychological state, health-related quality of life of patients suffering from this clinical condition. Moreover, global patient's condition and severity of the patient's symptoms are evaluated The secondary aim is to investigate the pathogenetic aspects of this clinical condition.

Read the detailed description

Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity. About 5% of women of reproductive age suffer from the disease.

The pelvis is the most frequent site of endometriotic lesion and three types of pelvic endometriosis can be clinically distinguished: peritoneal, ovarian, and deep infiltrating endometriosis.

However, endometriosis can also localize outside the pelvis: extra-pelvic foci may be found involving the umbilicus, omentum, appendix, liver, diaphragm, pleura and lungs, vulva, and surgical scars.

The majority of extrapelvic endometriosis implants are located in the skin, and most of them are of iatrogenic origin, following laparotomy, laparoscopic procedures, and episiotomies; only a minority of cases are of primary origin.

Umbilical endometriosis - first described by Villar in 1886 - is a very rare presentation of endometriosis, with a prevalence ranging from 0.5-1% of cases of extrapelvic endometriosis The proliferation and subsequent dissemination of iatrogenically implanted endometrial cells in laparotomy or laparoscopic scars would seem to be the cause of the occurrence of secondary umbilical endometriosis. Obviously this is not true in cases of primary umbilical endometriosis, in which case the pathogenic hypotheses include: hematic or lymphatic dissemination of endometrial cells from the peritoneum to the umbilicus through obliterated umbilical arteries; migration of endometrial cells through the venous or lymphatic circulation; metaplasia of urachus remnant or release of endometrial cells that during labor and delivery may contaminate the umbilical cord emergence. In 20% of cases, umbilical endometriosis is associated with pelvic endometriosis. In these patients, it is possible to speculate that endometriotic cells may migrate from the endometriotic implants to the umbilical site.

This migration process could be favored by fascia defects at the umbilical level. In fact, cases of umbilical endometriosis coexisting with umbilical hernia are described in the literature.

The clinical presentation consists of an umbilical nodule of variable color (red, blue, black, flesh-colored), ranging in size from 0.5 to 3 cm.

Pathognomonic symptoms are: bleeding and/or pain in the umbilical site of catamenial type, cutaneous hyperesthesia. Catamenial symptomatology associated with the nodule, which makes the diagnosis easier, is present in only 75% of cases.

In asymptomatic cases the nodule of umbilical endometriosis should be differentially diagnosed with hernia, hematoma or cyst and with some dermatological disorders such as pyogenic granuloma, umbilical polyp, melanocytic nevus, seborrheic keratosis, epithelial inclusion cysts, desmoid tumor, hemangioma and granular cell tumor. Furthermore, it should be ruled out that it is not a Sister Joseph's nodule, a sentinel of tumor metastasis, whose clinical symptomatology is similar to umbilical endometriosis, although the nodule tends to be more irregular and the symptoms non-cyclic. A case of umbilical metastasis from endometrial carcinoma, synchronous with umbilical endometriosis, is reported.

Instrumental examinations useful for differential diagnosis and definition of nodule size include soft tissue ultrasound, CT scan, and MRI.

Definitive diagnosis is provided only by histologic examination of the tissue. Exploratory laparoscopy is not indicated unless concomitant pelvic endometriosis is suspected.

The recommended treatment of umbilical endometriosis is surgical, consisting of complete removal of the endometriosis nodule, omphalectomy, and subsequent reconstruction of the umbilicus.

Recurrence rates after surgery are around 6% at 12 months in a large Japanese court, with no difference between taking and not taking postoperative hormonal therapy, while they are reduced to almost 0% in case of resection including a large portion of peritoneum.

Medical therapy, on the other hand, alleviates the associated algic symptoms by reducing the size of the nodule.

In the literature there are very few data on the efficacy of medical therapy; in a study with a very small number of cases an efficacy of 91.7% with dienogest and 51.1% with estroprogestinic pill is reported. There are no studies comparing medical and surgical therapy for the treatment of umbilical endometriosis.

Radical excision is recommended to avoid local recurrences and to avoid the risk of malignant transformation, although it is extremely rare (only 2 cases reported in the literature).

In literature, spontaneous resolution has been described in only one pregnant woman.

To date, there are few studies in the literature that have evaluated umbilical endometriosis.

Moreover, no study has ever formally compared the long-term efficacy of surgical or medical therapy for umbilical endometriosis.

This is an observational, retrospective/prospective and monocentric study; it is based on the review of medical records and on outpatient follow-up visits of patients in our clinic with umbilical endometriosis. This is a study design that it is best suited to a low prevalence of disease.

The principal aim of the study is the assessment of umbilical endometriosis cases in our clinic over the last 30 years in order to evaluate the effectiveness of medical and surgical treatments in terms of satisfaction, psychological state, health-related quality of life of patients suffering from this clinical condition. Moreover, global patient's condition and severity of the patient's symptoms are evaluated.

The secondary aim is to investigate the pathogenetic aspects of this clinical condition.

Being tested
Patients satisfaction after medical and surgical treatment for umbilical endometriosis
Keywords
Surgical treatment, Medical therapy, Satisfaction
Medical subject headings
Endometriosis, Personal Satisfaction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Patients satisfaction after medical and surgical treatment for umbilical endometriosisOther

    It is a retrospectively evaluation of cases of umbilical endometriosis in our clinic over the last 30 years, based on the review of medical records and on outpatient follow-up visits. The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period. If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Degree of patient satisfaction

    a five-level Likert scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied) to evaluate the effectiveness of medical and surgical treatments for umbilical endometriosis.

    Measured: 30 years

  2. The patient's global condition

    Patients' Global Impression of Change (PGIC) scale, a composed of seven levels (greatly improved, much improved, minimally improved, unchanged, minimally worsened, very worsened, greatly worsened) to evaluate the effectiveness of medical and surgical treatments for umbilical endometriosis.

    Measured: 30 years

  3. Severity of symptoms

    Patients' Global Impression of Severity (PGIS) scale, a scale consisting of five levels (none, mild, moderate, severe, very severe)

    Measured: 30 years

  4. HADS- Hospital Anxiety and Depression Scale

    The HADS questionnaire is a self-assessment mood scale specifically designed for use in non-psychiatric hospital outpatients to determine states of anxiety and depression. It comprises 14 questions, 7 for the anxiety subscale and 7 for the depression subscale.

    Measured: 30 years

  5. The Short Form Survey, SF-12

    The SF-12 health survey, developed from the original SF-36 questionnaire, is a well-known, validated, selfadministered 12-item instrument. It measures health dimensions covering functional status, well-being, and overall health. Information from the 12 items is used to construct Physical Component Summary (PCS-12) and Mental Component Summary (MCS-12) measures, with higher scores indicating better health perception.

    Measured: 30 years

Secondary outcomes (2)
  1. Pathogenetic aspects

    Study of the pathogenesis on a case-by-case basis depending on the patient's previous physiological and pathological medical history.

    Measured: 30 years

  2. Comparison between medical and surgical therapy

    Comparison through the degree of patient satisfaction, evaluated with Likert scale (used for 1st primary outcome)

    Measured: 30 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2022
  2. Study start1 Mar 2022
  3. Primary completion1 Jun 2022 (estimated)
  4. Study completion1 Jun 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05367258
Sponsor's protocol ID
2283
Acronym
UMBEND
Status last verified
May 2022
First submitted
5 May 2022
Last updated
10 May 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Endometriosis of Umbilicus and Endometriosis in Scar of Skin, run by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Nicola Berlanda, Professor (0255032318, nicola.berlanda@policlinico.mi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Degree of patient satisfaction (time frame: 30 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in